AvingerNASDAQ: AVGR

REDWOOD CITY, CA / ACCESSWIRE / September 18, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced the issuance of a new U.S. patent and the allowance of five additional U.S. patents that are expected to issue over the next four months. These patents expand intellectual property protection for Avinger's proprietary image-guided system and devices for both peripheral and coronary applications.

Avinger (AVGR) fully launches Pantheris LV, the first image-guided atherectomy system for large vessels, thus enhancing peripheral artery disease treatment with advanced technology.

REDWOOD CITY, CA / ACCESSWIRE / August 20, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced full commercial launch of the Pantheris LV image-guided directional atherectomy system. With the initiation of full commercial launch, all current and prospective accounts can now order the Pantheris LV device, a line extension of the first and only image-guided atherectomy device for the treatment of peripheral artery disease (PAD).

Avinger (AVGR) came out with a quarterly loss of $2.82 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $8.85 per share a year ago.

Implements Lower Operating Cost Profile, Readying OCT-Guided Coronary Device for IDE Submission REDWOOD CITY, CA / ACCESSWIRE / August 8, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the second quarter ended June 30, 2024. Second Quarter and Recent Highlights Reported second quarter 2024 revenue of $1.8 million, with a sequentially increased gross margin of 20% Streamlined operating costs in June 2024 to provide support for its existing peripheral user base while advancing coronary product line development, with the full effect of the cost reductions expected to be seen in the second half of 2024 Continued Phase III verification and validation studies for Avinger's proprietary image-guided coronary CTO-crossing system for IDE submission anticipated in the third quarter of 2024 Building product inventory for full commercial launch of the new Pantheris LV (large vessel) image-guided atherectomy device in the coming weeks Announced the appointment of Thomas Davis, MD, FACC, a highly experienced interventional cardiologist and pre-eminent leader in the treatment of vascular disease, as Chief Medical Officer Completed the conversion of $11 million of debt into shares of a new series of convertible preferred stock, reducing the outstanding principal amount of debt to $2.6 million with no principal payments until 2027 Secured up to $24 million in additional growth financing, with $6 million funded in June 2024 and up to an additional $18 million available based upon the exercise in full of coronary clinical milestone-linked warrants "The Phase III verification and validation studies for our innovative coronary CTO solution remain on track for filing an IDE application by the end of the third quarter," said Jeff Soinski, Avinger's President and CEO.

REDWOOD CITY, CA / ACCESSWIRE / August 5, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced the appointment of Thomas P. Davis, MD, FACC, as Chief Medical Officer for its peripheral business.

REDWOOD CITY, CA / ACCESSWIRE / July 29, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the second quarter 2024 after the close of trading on Thursday, August 8, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.

$6 million upfront with up to an additional $18 million of aggregate gross proceeds upon the exercise in full of clinical milestone-linked Series Warrants REDWOOD CITY, CA / ACCESSWIRE / June 17, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced the closing its previously announced public offering of an aggregate of 3,614,457 shares of its common stock (or common stock equivalents in lieu thereof), Series A-1 warrants to purchase up to 3,614,457 shares of common stock, Series A-2 warrants to purchase up to 3,614,457 shares of common stock and Series A-3 warrants to purchase up to 3,614,457 shares of common stock (all the warrants, collectively, the "Series Warrants"), at a combined public offering price of $1.66 per share (or per common stock equivalent in lieu thereof) and accompanying Series Warrants. The Series Warrants have an exercise price of $1.66 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series Warrants.

Avinger, Inc., a medical device company based in Redwood City, CA, announced on May 16, 2024, that they have converted $11 million, or about 80% of their current debt with CRG Partners III L.P., into shares of a new series of convertible preferred stock.